Drug Profile
Mulundocandin
Alternative Names: MCNLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator Aventis
- Class Antifungals
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 13 Nov 2001 No-Development-Reported for Mycoses in France (Unknown route)
- 13 Nov 2001 No-Development-Reported for Mycoses in Germany (Unknown route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma